Summary
This Form 8-K filing from Pfizer Inc. (PFE) dated June 14, 2007, clarifies previously announced findings from a retrospective analysis of a U.S. managed-care database concerning Lipitor. Initially, Pfizer reported significant additional cardiovascular risk reductions for Lipitor compared to simvastatin in both primary and secondary analyses. However, upon subsequent review, the company has revised these findings. The primary analysis, which adjusted for expected LDL cholesterol differences, now shows a 10% additional risk reduction for Lipitor, which is not statistically significant. The secondary analysis, examining risk reduction from day one of therapy, still shows a statistically significant 22% additional risk reduction for Lipitor.
Key Highlights
- 1Pfizer is clarifying previous announcements regarding a Lipitor cardiovascular risk reduction study.
- 2A retrospective analysis of a U.S. managed-care database compared Lipitor and simvastatin.
- 3The primary analysis, after adjusting for LDL cholesterol levels, showed a 10% additional cardiovascular risk reduction for Lipitor, which is not statistically significant.
- 4The secondary analysis, looking at risk reduction from day one of therapy, showed a statistically significant 22% additional cardiovascular risk reduction for Lipitor.
- 5The initial announcement had reported a 14% statistically significant reduction in the primary analysis and a 26% statistically significant reduction in the secondary analysis.
- 6This filing serves to correct and provide more precise data on the comparative effectiveness of Lipitor versus simvastatin in reducing cardiovascular events.